Skip to main content
Top
Published in: AIDS Research and Therapy 1/2014

Open Access 01-12-2014 | Research

Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort

Authors: Sureshnee Pillay, Ruth M Bland, Richard J Lessells, Justen Manasa, Tulio de Oliveira, Sivapragashini Danaviah

Published in: AIDS Research and Therapy | Issue 1/2014

Login to get access

Abstract

Background

Better understanding of drug resistance patterns in HIV-infected children on antiretroviral therapy (ART) is required to inform public health policies in high prevalence settings. The aim of this study was to characterise the acquired drug resistance in HIV-infected children failing first-line ART in a decentralised rural HIV programme.

Methods

Plasma samples were collected from 101 paediatric patients (≤15 yrs of age) identified as failing ART. RNA was extracted from the plasma, reverse transcribed and a 1.3 kb region of the pol gene was amplified and sequenced using Sanger sequencing protocols. Sequences were edited in Geneious and drug resistance mutations were identified using the RegaDB and the Stanford resistance algorithms. The prevalence and frequency of mutations were analysed together with selected clinical and demographic data in STATA v11.

Results

A total of 101 children were enrolled and 89 (88%) were successfully genotyped; 73 on a non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen and 16 on a protease inhibitor (PI)-based regimen at the time of genotyping. The majority of patients on an NNRTI regimen (80%) had both nucleoside reverse-transcriptase inhibitor (NRTI) and NNRTI resistance mutations. M184V and K103N were the most common mutations amongst children on NNRTI-based and M184V among children on PI-based regimens. 30.1% had one or more thymidine analogue mutation (TAM) and 6% had ≥3 TAMs. Only one child on a PI-based regimen harboured a major PI resistance mutation.

Conclusions

Whilst the patterns of resistance were largely predictable, the few complex resistance patterns seen with NNRTI-based regimens and the absence of major PI mutations in children failing PI-based regimens suggest the need for wider access to genotypic resistance testing in this setting.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Meyers T: Changes in pediatric HIV-related hospital admissions and mortality in Soweto, South Africa, 1996–2011: light at the end of the tunnel?. J Acquir Immune Defic Syndr. 2012, 60 (5): 503-510. 10.1097/QAI.0b013e318256b4f8PubMedCentralCrossRefPubMed Meyers T: Changes in pediatric HIV-related hospital admissions and mortality in Soweto, South Africa, 1996–2011: light at the end of the tunnel?. J Acquir Immune Defic Syndr. 2012, 60 (5): 503-510. 10.1097/QAI.0b013e318256b4f8PubMedCentralCrossRefPubMed
3.
go back to reference Bland RM: Management of HIV-infected children in Africa: progress and challenges. Arch Dis Child. 2011, 96 (10): 911-915. 10.1136/adc.2010.193789CrossRefPubMed Bland RM: Management of HIV-infected children in Africa: progress and challenges. Arch Dis Child. 2011, 96 (10): 911-915. 10.1136/adc.2010.193789CrossRefPubMed
4.
5.
go back to reference Davies MA: Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J. 2009, 99 (10): 730-737.PubMedCentralPubMed Davies MA: Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J. 2009, 99 (10): 730-737.PubMedCentralPubMed
6.
go back to reference Mofenson LM, Cotton MF: The challenges of success: adolescents with perinatal HIV infection. J Int AIDS Soc. 2013, 16: 18650-PubMedCentralPubMed Mofenson LM, Cotton MF: The challenges of success: adolescents with perinatal HIV infection. J Int AIDS Soc. 2013, 16: 18650-PubMedCentralPubMed
7.
8.
go back to reference Sigaloff KC: HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis. 2011, 11 (10): 769-779. 10.1016/S1473-3099(11)70141-4CrossRefPubMed Sigaloff KC: HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis. 2011, 11 (10): 769-779. 10.1016/S1473-3099(11)70141-4CrossRefPubMed
9.
go back to reference Meyers T: Challenges to pediatric HIV care and treatment in South Africa. J Infect Dis. 2007, 196 (Suppl 3): S474-S481.CrossRefPubMed Meyers T: Challenges to pediatric HIV care and treatment in South Africa. J Infect Dis. 2007, 196 (Suppl 3): S474-S481.CrossRefPubMed
10.
go back to reference Fatti G: Increased vulnerability of rural children on antiretroviral therapy attending public health facilities in South Africa: a retrospective cohort study. J Int AIDS Soc. 2010, 13: 46- 10.1186/1758-2652-13-46PubMedCentralCrossRefPubMed Fatti G: Increased vulnerability of rural children on antiretroviral therapy attending public health facilities in South Africa: a retrospective cohort study. J Int AIDS Soc. 2010, 13: 46- 10.1186/1758-2652-13-46PubMedCentralCrossRefPubMed
11.
go back to reference Macdonald P: Paediatric human immunodeficiency virus treatment outcomes from a resource-limited setting in south africa: highly active antiretroviral therapy alone is not enough. Vulnerable Child Youth Stud. 2011, 6 (3): 208-221. 10.1080/17450128.2011.580020.CrossRef Macdonald P: Paediatric human immunodeficiency virus treatment outcomes from a resource-limited setting in south africa: highly active antiretroviral therapy alone is not enough. Vulnerable Child Youth Stud. 2011, 6 (3): 208-221. 10.1080/17450128.2011.580020.CrossRef
12.
go back to reference Wallis CL: Emergence of drug resistance in HIV-1 subtype C infected children failing the South African National Antiretroviral roll-out program. Paeiatric I nfectious Dis J. 2009, 38 (12): 1123-1125. Wallis CL: Emergence of drug resistance in HIV-1 subtype C infected children failing the South African National Antiretroviral roll-out program. Paeiatric I nfectious Dis J. 2009, 38 (12): 1123-1125.
13.
go back to reference Barth RE: Long-term outcome of children receiving antiretroviral treatment in Rural South Africa. Pediatr Infect Dis J. 2011, 30 (1): 52-56. 10.1097/INF.0b013e3181ed2af3CrossRefPubMed Barth RE: Long-term outcome of children receiving antiretroviral treatment in Rural South Africa. Pediatr Infect Dis J. 2011, 30 (1): 52-56. 10.1097/INF.0b013e3181ed2af3CrossRefPubMed
14.
go back to reference van Zyl G: Protease inhibitor resistance in South African children with virologic failure. Pediatr Infect Dis J. 2009, 28 (12): 1125-1127. 10.1097/INF.0b013e3181af829dCrossRefPubMed van Zyl G: Protease inhibitor resistance in South African children with virologic failure. Pediatr Infect Dis J. 2009, 28 (12): 1125-1127. 10.1097/INF.0b013e3181af829dCrossRefPubMed
15.
go back to reference Pillay V: HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008, 24 (11): 1449-1454. 10.1089/aid.2008.0180CrossRefPubMed Pillay V: HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008, 24 (11): 1449-1454. 10.1089/aid.2008.0180CrossRefPubMed
16.
go back to reference Taylor BS: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than Two years of Age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011, 27 (9): 945-956. 10.1089/aid.2010.0205PubMedCentralCrossRefPubMed Taylor BS: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than Two years of Age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011, 27 (9): 945-956. 10.1089/aid.2010.0205PubMedCentralCrossRefPubMed
17.
go back to reference Green TN: Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. AIDS Res Hum Retroviruses. 2012, 28 (4): 324-332. 10.1089/aid.2011.0106PubMedCentralCrossRefPubMed Green TN: Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. AIDS Res Hum Retroviruses. 2012, 28 (4): 324-332. 10.1089/aid.2011.0106PubMedCentralCrossRefPubMed
18.
go back to reference Latinovic O: Pharmacotherapy of HIV-1 infection: focus on CCR5 antagonist maraviroc. Clin Med Ther. 2009, 1: 1497-1510.PubMedCentralPubMed Latinovic O: Pharmacotherapy of HIV-1 infection: focus on CCR5 antagonist maraviroc. Clin Med Ther. 2009, 1: 1497-1510.PubMedCentralPubMed
19.
go back to reference Manasa J: High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa. PLoS One. 2013, 0-in press Manasa J: High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa. PLoS One. 2013, 0-in press
20.
go back to reference Osterholzer D: The role of etravirine in the management of treatment-experienced pediatric patients with HIV. HIV AIDS (Auckl). 2013, 5: 67-73. Osterholzer D: The role of etravirine in the management of treatment-experienced pediatric patients with HIV. HIV AIDS (Auckl). 2013, 5: 67-73.
21.
go back to reference Frange P: Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure. PaedPaediatric Infec Dis J. 2011, 30 (8): 684-688. 10.1097/INF.0b013e31821752d6.CrossRef Frange P: Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure. PaedPaediatric Infec Dis J. 2011, 30 (8): 684-688. 10.1097/INF.0b013e31821752d6.CrossRef
22.
go back to reference Orrel C: Resistance in pediatric patients experiencing virologic failure with first- and second-line antiretroviral therapy. Paediatric Infec Dis J. 2013, 32 (6): 644-647. 10.1097/INF.0b013e3182829092.CrossRef Orrel C: Resistance in pediatric patients experiencing virologic failure with first- and second-line antiretroviral therapy. Paediatric Infec Dis J. 2013, 32 (6): 644-647. 10.1097/INF.0b013e3182829092.CrossRef
23.
go back to reference Wallis CL: Low rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance detected in a well monitored cohort in South Africa accessing antiretroviral therapy. Antivir Ther. 2012, 17 (2): 313-320.PubMedCentralCrossRefPubMed Wallis CL: Low rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance detected in a well monitored cohort in South Africa accessing antiretroviral therapy. Antivir Ther. 2012, 17 (2): 313-320.PubMedCentralCrossRefPubMed
24.
go back to reference Pillay D: Implications of HIV drug resistance on first and second line therapies in resource limited settings :report froma workshop organised by the collaborative HIV and anti-HIV drug resistance network. Antivir Ther. 2013, 18 (6): 831-836. 10.3851/IMP2650CrossRefPubMed Pillay D: Implications of HIV drug resistance on first and second line therapies in resource limited settings :report froma workshop organised by the collaborative HIV and anti-HIV drug resistance network. Antivir Ther. 2013, 18 (6): 831-836. 10.3851/IMP2650CrossRefPubMed
25.
go back to reference Doyon L: Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 1996, 70 (6): 3763-3769.PubMedCentralPubMed Doyon L: Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 1996, 70 (6): 3763-3769.PubMedCentralPubMed
27.
go back to reference Cooke GS: Need for timely paediatric HIV treatment within primary health care in rural South Africa. PLoS One. 2009, 4 (9): e7101- 10.1371/journal.pone.0007101PubMedCentralCrossRefPubMed Cooke GS: Need for timely paediatric HIV treatment within primary health care in rural South Africa. PLoS One. 2009, 4 (9): e7101- 10.1371/journal.pone.0007101PubMedCentralCrossRefPubMed
28.
go back to reference de Oliveira T, Shafer RW, Seebregts C: Public database for HIV drug resistance in southern Africa. Nature. 2010, 464 (7289): 673-CrossRefPubMed de Oliveira T, Shafer RW, Seebregts C: Public database for HIV drug resistance in southern Africa. Nature. 2010, 464 (7289): 673-CrossRefPubMed
29.
go back to reference Libin P: RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics. 2013, 29 (11): 1477-1480. 10.1093/bioinformatics/btt162PubMedCentralCrossRefPubMed Libin P: RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics. 2013, 29 (11): 1477-1480. 10.1093/bioinformatics/btt162PubMedCentralCrossRefPubMed
30.
go back to reference Alcantara LC: A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res. 2009, 37 (Web Server issue): W634-W642.PubMedCentralCrossRefPubMed Alcantara LC: A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res. 2009, 37 (Web Server issue): W634-W642.PubMedCentralCrossRefPubMed
31.
go back to reference de Oliveira T: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005, 21 (19): 3797-3800. 10.1093/bioinformatics/bti607CrossRefPubMed de Oliveira T: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005, 21 (19): 3797-3800. 10.1093/bioinformatics/bti607CrossRefPubMed
32.
go back to reference Johnson VA: Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013, 21 (1): 6-14.PubMed Johnson VA: Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013, 21 (1): 6-14.PubMed
Metadata
Title
Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort
Authors
Sureshnee Pillay
Ruth M Bland
Richard J Lessells
Justen Manasa
Tulio de Oliveira
Sivapragashini Danaviah
Publication date
01-12-2014
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2014
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/1742-6405-11-3

Other articles of this Issue 1/2014

AIDS Research and Therapy 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.